Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastritis | 106 | 2024 | 370 | 20.660 |
Why?
|
Helicobacter Infections | 167 | 2024 | 1255 | 16.550 |
Why?
|
Helicobacter pylori | 161 | 2024 | 1313 | 14.190 |
Why?
|
Gastric Mucosa | 93 | 2024 | 483 | 11.060 |
Why?
|
Stomach Neoplasms | 69 | 2024 | 538 | 10.280 |
Why?
|
Celiac Disease | 16 | 2023 | 69 | 6.880 |
Why?
|
Gastritis, Atrophic | 27 | 2024 | 60 | 6.850 |
Why?
|
Colitis, Microscopic | 11 | 2023 | 15 | 6.790 |
Why?
|
Inflammatory Bowel Diseases | 15 | 2023 | 313 | 6.490 |
Why?
|
Eosinophilic Esophagitis | 23 | 2022 | 74 | 6.480 |
Why?
|
Precancerous Conditions | 26 | 2023 | 288 | 5.940 |
Why?
|
Enteritis | 17 | 2024 | 54 | 5.490 |
Why?
|
Biopsy | 97 | 2023 | 1239 | 5.400 |
Why?
|
Eosinophilia | 20 | 2024 | 101 | 4.520 |
Why?
|
Stomach | 36 | 2022 | 271 | 4.470 |
Why?
|
Adenoma | 14 | 2022 | 133 | 4.330 |
Why?
|
Duodenitis | 9 | 2024 | 14 | 4.330 |
Why?
|
Colonic Polyps | 10 | 2022 | 78 | 4.050 |
Why?
|
Gastroesophageal Reflux | 20 | 2020 | 289 | 3.830 |
Why?
|
Polyps | 10 | 2020 | 48 | 3.510 |
Why?
|
Metaplasia | 41 | 2023 | 216 | 3.280 |
Why?
|
Adenocarcinoma | 26 | 2022 | 991 | 2.940 |
Why?
|
Colonic Neoplasms | 9 | 2022 | 247 | 2.760 |
Why?
|
Prevalence | 46 | 2024 | 2393 | 2.580 |
Why?
|
Intestinal Mucosa | 24 | 2018 | 765 | 2.490 |
Why?
|
Esophagitis | 9 | 2023 | 40 | 2.410 |
Why?
|
Humans | 365 | 2024 | 122996 | 2.410 |
Why?
|
Duodenum | 17 | 2023 | 99 | 2.350 |
Why?
|
Eosinophils | 18 | 2024 | 121 | 2.310 |
Why?
|
Esophagus | 14 | 2023 | 212 | 2.300 |
Why?
|
Middle Aged | 149 | 2024 | 25931 | 2.250 |
Why?
|
Aged | 112 | 2024 | 19035 | 2.130 |
Why?
|
Colonoscopy | 16 | 2022 | 239 | 2.090 |
Why?
|
Crohn Disease | 8 | 2023 | 283 | 2.080 |
Why?
|
Colitis, Collagenous | 3 | 2022 | 3 | 2.020 |
Why?
|
Barrett Esophagus | 14 | 2020 | 341 | 2.000 |
Why?
|
Adult | 149 | 2024 | 28980 | 1.980 |
Why?
|
Case-Control Studies | 32 | 2023 | 3259 | 1.940 |
Why?
|
Male | 193 | 2024 | 59901 | 1.850 |
Why?
|
Aged, 80 and over | 53 | 2021 | 6359 | 1.800 |
Why?
|
Endoscopy, Digestive System | 12 | 2020 | 154 | 1.720 |
Why?
|
Endoscopy, Gastrointestinal | 19 | 2022 | 243 | 1.700 |
Why?
|
Strongyloidiasis | 28 | 1996 | 43 | 1.680 |
Why?
|
Female | 161 | 2024 | 65309 | 1.640 |
Why?
|
Stomach Diseases | 8 | 2015 | 56 | 1.530 |
Why?
|
Colorectal Neoplasms | 8 | 2022 | 560 | 1.480 |
Why?
|
Pathology | 5 | 2016 | 39 | 1.420 |
Why?
|
Granuloma | 3 | 2024 | 67 | 1.410 |
Why?
|
Young Adult | 43 | 2024 | 8840 | 1.400 |
Why?
|
Proton Pump Inhibitors | 10 | 2019 | 253 | 1.370 |
Why?
|
Gastrointestinal Diseases | 9 | 2024 | 335 | 1.360 |
Why?
|
Databases, Factual | 15 | 2021 | 1166 | 1.360 |
Why?
|
Guideline Adherence | 5 | 2017 | 375 | 1.290 |
Why?
|
Colitis, Lymphocytic | 2 | 2022 | 2 | 1.270 |
Why?
|
Staining and Labeling | 8 | 2018 | 183 | 1.220 |
Why?
|
Cardia | 6 | 2010 | 27 | 1.170 |
Why?
|
United States | 41 | 2021 | 10595 | 1.160 |
Why?
|
Cross-Sectional Studies | 19 | 2022 | 3359 | 1.150 |
Why?
|
Colon | 6 | 2015 | 353 | 1.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 11 | 2013 | 61 | 1.110 |
Why?
|
Adolescent | 45 | 2024 | 19029 | 1.080 |
Why?
|
Pathology, Clinical | 4 | 2016 | 23 | 1.060 |
Why?
|
Gastrointestinal Neoplasms | 5 | 2010 | 80 | 1.040 |
Why?
|
Gastrointestinal Tract | 6 | 2024 | 208 | 1.040 |
Why?
|
Odds Ratio | 15 | 2021 | 1245 | 1.030 |
Why?
|
Atrophy | 21 | 2022 | 225 | 1.020 |
Why?
|
Immunohistochemistry | 20 | 2019 | 1684 | 1.010 |
Why?
|
Risk Factors | 34 | 2024 | 9974 | 1.000 |
Why?
|
Lymphocytosis | 2 | 2019 | 14 | 1.000 |
Why?
|
Intestines | 15 | 2015 | 571 | 0.990 |
Why?
|
Age Distribution | 11 | 2021 | 410 | 0.950 |
Why?
|
Gastric Acid | 4 | 2019 | 50 | 0.940 |
Why?
|
Colitis, Ulcerative | 5 | 2023 | 208 | 0.930 |
Why?
|
Duodenal Neoplasms | 3 | 2014 | 22 | 0.920 |
Why?
|
Duodenal Ulcer | 18 | 2020 | 127 | 0.900 |
Why?
|
Anti-Ulcer Agents | 14 | 2003 | 111 | 0.880 |
Why?
|
Peptic Ulcer | 14 | 2020 | 147 | 0.880 |
Why?
|
Child | 39 | 2022 | 24144 | 0.840 |
Why?
|
Pyloric Antrum | 18 | 2007 | 64 | 0.830 |
Why?
|
Duodenal Diseases | 3 | 2017 | 34 | 0.830 |
Why?
|
Intestinal Neoplasms | 4 | 2019 | 39 | 0.820 |
Why?
|
Esophagogastric Junction | 4 | 2020 | 28 | 0.810 |
Why?
|
Histocytochemistry | 7 | 2016 | 98 | 0.810 |
Why?
|
Gastroenterology | 5 | 2017 | 191 | 0.800 |
Why?
|
Colitis | 8 | 2018 | 152 | 0.790 |
Why?
|
Strongyloides | 15 | 1989 | 16 | 0.780 |
Why?
|
Helicobacter | 4 | 2018 | 17 | 0.770 |
Why?
|
Esophageal Neoplasms | 6 | 2016 | 360 | 0.740 |
Why?
|
Adenomatous Polyps | 2 | 2020 | 13 | 0.720 |
Why?
|
Famous Persons | 3 | 2016 | 15 | 0.680 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2019 | 10 | 0.680 |
Why?
|
Child, Preschool | 24 | 2020 | 13819 | 0.680 |
Why?
|
Infant | 21 | 2020 | 12286 | 0.660 |
Why?
|
Carcinoid Tumor | 2 | 2013 | 25 | 0.640 |
Why?
|
Colonic Diseases | 2 | 2017 | 38 | 0.630 |
Why?
|
Sex Distribution | 6 | 2021 | 294 | 0.630 |
Why?
|
Mast Cells | 5 | 2024 | 74 | 0.630 |
Why?
|
Terminology as Topic | 8 | 2015 | 229 | 0.620 |
Why?
|
Logistic Models | 8 | 2018 | 1796 | 0.610 |
Why?
|
Esophagitis, Peptic | 4 | 2016 | 33 | 0.610 |
Why?
|
Alcian Blue | 1 | 2018 | 3 | 0.610 |
Why?
|
Periodic Acid | 1 | 2018 | 7 | 0.610 |
Why?
|
Mucositis | 1 | 2018 | 18 | 0.600 |
Why?
|
Chronic Disease | 17 | 2022 | 1166 | 0.600 |
Why?
|
Predictive Value of Tests | 15 | 2018 | 2105 | 0.600 |
Why?
|
Stomach Ulcer | 11 | 2020 | 92 | 0.600 |
Why?
|
Esophageal Mucosa | 1 | 2017 | 10 | 0.580 |
Why?
|
Diarrhea | 4 | 2015 | 315 | 0.580 |
Why?
|
Carcinoma, Signet Ring Cell | 2 | 2015 | 10 | 0.550 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2014 | 73 | 0.550 |
Why?
|
Hyperplasia | 8 | 2022 | 210 | 0.530 |
Why?
|
Retrospective Studies | 26 | 2023 | 15930 | 0.530 |
Why?
|
Prognosis | 13 | 2018 | 4490 | 0.520 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 868 | 0.520 |
Why?
|
Digestive System Diseases | 1 | 2016 | 17 | 0.520 |
Why?
|
Anti-Bacterial Agents | 16 | 2021 | 2395 | 0.510 |
Why?
|
Multivariate Analysis | 6 | 2018 | 1417 | 0.500 |
Why?
|
Epithelioid Cells | 1 | 2014 | 11 | 0.490 |
Why?
|
Parietal Cells, Gastric | 2 | 2022 | 37 | 0.490 |
Why?
|
Follow-Up Studies | 16 | 2022 | 5031 | 0.480 |
Why?
|
Ileal Diseases | 2 | 2010 | 21 | 0.460 |
Why?
|
Neoplasm Staging | 9 | 2019 | 1215 | 0.460 |
Why?
|
Omeprazole | 12 | 2019 | 98 | 0.460 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 1253 | 0.460 |
Why?
|
Neuroendocrine Tumors | 1 | 2014 | 52 | 0.460 |
Why?
|
Medical Errors | 2 | 2006 | 155 | 0.460 |
Why?
|
Intestine, Small | 5 | 2013 | 302 | 0.460 |
Why?
|
Choristoma | 2 | 2012 | 49 | 0.450 |
Why?
|
Intestinal Obstruction | 1 | 2015 | 97 | 0.450 |
Why?
|
Prospective Studies | 15 | 2024 | 6023 | 0.440 |
Why?
|
Sex Factors | 7 | 2017 | 1254 | 0.440 |
Why?
|
Immunoglobulin G | 18 | 2009 | 771 | 0.440 |
Why?
|
Gastrectomy | 2 | 2012 | 89 | 0.440 |
Why?
|
Gastrins | 5 | 2008 | 32 | 0.430 |
Why?
|
Antigens, Bacterial | 8 | 2004 | 314 | 0.430 |
Why?
|
Neuroendocrine Cells | 1 | 2013 | 9 | 0.430 |
Why?
|
Diagnosis, Differential | 9 | 2014 | 1870 | 0.420 |
Why?
|
Severity of Illness Index | 13 | 2022 | 2837 | 0.420 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2012 | 42 | 0.410 |
Why?
|
Registries | 2 | 2018 | 1382 | 0.410 |
Why?
|
Risk Assessment | 8 | 2024 | 3325 | 0.410 |
Why?
|
Gastroparesis | 1 | 2013 | 66 | 0.400 |
Why?
|
Biomedical Research | 2 | 2017 | 519 | 0.400 |
Why?
|
Antibodies, Bacterial | 6 | 2009 | 382 | 0.390 |
Why?
|
Leukocyte Count | 9 | 2020 | 247 | 0.380 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 1684 | 0.380 |
Why?
|
Lymphocytes | 3 | 2016 | 403 | 0.380 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 614 | 0.380 |
Why?
|
Arsenic Poisoning | 1 | 2011 | 5 | 0.370 |
Why?
|
Age Factors | 6 | 2017 | 2801 | 0.370 |
Why?
|
Autoantibodies | 2 | 2013 | 422 | 0.360 |
Why?
|
Disease Management | 2 | 2020 | 515 | 0.360 |
Why?
|
Gastric Mucins | 3 | 1998 | 5 | 0.360 |
Why?
|
Aging | 2 | 2015 | 1172 | 0.360 |
Why?
|
Gastroscopy | 6 | 2013 | 102 | 0.360 |
Why?
|
Urease | 9 | 2002 | 72 | 0.350 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2011 | 93 | 0.350 |
Why?
|
Ileum | 1 | 2010 | 132 | 0.340 |
Why?
|
Disease Progression | 10 | 2019 | 2027 | 0.340 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 5 | 2012 | 304 | 0.340 |
Why?
|
Gastric Fundus | 1 | 2009 | 9 | 0.330 |
Why?
|
Biopsy, Needle | 3 | 2019 | 230 | 0.330 |
Why?
|
Sensitivity and Specificity | 17 | 2016 | 2021 | 0.320 |
Why?
|
Italy | 5 | 2018 | 112 | 0.320 |
Why?
|
Cause of Death | 1 | 2011 | 458 | 0.310 |
Why?
|
Endoscopy | 7 | 2024 | 283 | 0.310 |
Why?
|
Bacterial Adhesion | 3 | 1998 | 108 | 0.310 |
Why?
|
Incidence | 8 | 2018 | 3047 | 0.310 |
Why?
|
Pathologists | 3 | 2024 | 29 | 0.310 |
Why?
|
Heartburn | 3 | 2023 | 15 | 0.300 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2012 | 619 | 0.290 |
Why?
|
Bacterial Proteins | 10 | 2004 | 875 | 0.290 |
Why?
|
Lymphoid Tissue | 5 | 1999 | 44 | 0.290 |
Why?
|
Seasons | 3 | 2019 | 303 | 0.290 |
Why?
|
Mastocytosis | 2 | 2024 | 7 | 0.290 |
Why?
|
AIDS-Related Opportunistic Infections | 8 | 1996 | 138 | 0.280 |
Why?
|
Autoantigens | 3 | 2004 | 120 | 0.280 |
Why?
|
Secondary Prevention | 2 | 2019 | 211 | 0.280 |
Why?
|
Infant, Newborn | 9 | 2020 | 8070 | 0.280 |
Why?
|
Interprofessional Relations | 1 | 2008 | 144 | 0.270 |
Why?
|
Specimen Handling | 5 | 2016 | 142 | 0.270 |
Why?
|
Cohort Studies | 6 | 2017 | 4705 | 0.270 |
Why?
|
Observer Variation | 6 | 2020 | 302 | 0.270 |
Why?
|
Physician's Role | 1 | 2008 | 164 | 0.270 |
Why?
|
Intestinal Diseases, Parasitic | 5 | 1995 | 38 | 0.260 |
Why?
|
Geography, Medical | 2 | 2017 | 16 | 0.260 |
Why?
|
Wheat Hypersensitivity | 1 | 2005 | 3 | 0.260 |
Why?
|
Enterochromaffin-like Cells | 2 | 2003 | 3 | 0.250 |
Why?
|
Bismuth | 9 | 1999 | 79 | 0.250 |
Why?
|
Dyspepsia | 5 | 2018 | 101 | 0.240 |
Why?
|
Deglutition Disorders | 3 | 2023 | 125 | 0.240 |
Why?
|
Chi-Square Distribution | 3 | 2012 | 587 | 0.240 |
Why?
|
Amoxicillin | 8 | 1997 | 119 | 0.240 |
Why?
|
Truth Disclosure | 1 | 2006 | 103 | 0.240 |
Why?
|
Publishing | 1 | 2006 | 108 | 0.240 |
Why?
|
Desensitization, Immunologic | 1 | 2005 | 95 | 0.230 |
Why?
|
Immunoglobulin E | 9 | 1989 | 158 | 0.230 |
Why?
|
Tetracycline | 7 | 1997 | 78 | 0.230 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 49 | 0.220 |
Why?
|
Animals | 45 | 2024 | 33693 | 0.220 |
Why?
|
Calcium-Binding Proteins | 2 | 2011 | 327 | 0.220 |
Why?
|
Quinolones | 1 | 2003 | 54 | 0.210 |
Why?
|
Mucous Membrane | 3 | 2011 | 84 | 0.210 |
Why?
|
Esomeprazole | 1 | 2003 | 31 | 0.210 |
Why?
|
Salicylates | 7 | 1999 | 53 | 0.210 |
Why?
|
Apoptosis | 4 | 2018 | 1783 | 0.210 |
Why?
|
HIV Infections | 2 | 2014 | 1864 | 0.210 |
Why?
|
Comorbidity | 2 | 2018 | 1498 | 0.210 |
Why?
|
Puerto Rico | 3 | 2013 | 41 | 0.210 |
Why?
|
Alanine | 1 | 2003 | 181 | 0.210 |
Why?
|
Disease Models, Animal | 14 | 2013 | 4263 | 0.210 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 48 | 0.210 |
Why?
|
Drug Therapy, Combination | 18 | 2019 | 1148 | 0.210 |
Why?
|
Organometallic Compounds | 7 | 1999 | 106 | 0.200 |
Why?
|
Veterans | 4 | 2019 | 1725 | 0.200 |
Why?
|
Reagent Strips | 3 | 1997 | 11 | 0.200 |
Why?
|
Outpatients | 2 | 2022 | 254 | 0.200 |
Why?
|
Paraffin Embedding | 2 | 2021 | 30 | 0.200 |
Why?
|
Autoimmune Diseases | 2 | 2015 | 249 | 0.200 |
Why?
|
Lymphoma, B-Cell | 1 | 2003 | 135 | 0.190 |
Why?
|
Metronidazole | 8 | 1997 | 155 | 0.190 |
Why?
|
Linear Models | 2 | 2015 | 671 | 0.190 |
Why?
|
Breath Tests | 5 | 2002 | 179 | 0.190 |
Why?
|
Stem Cells | 2 | 2017 | 701 | 0.190 |
Why?
|
History, 19th Century | 3 | 2016 | 118 | 0.190 |
Why?
|
Blood Platelets | 1 | 2004 | 333 | 0.190 |
Why?
|
Tissue Fixation | 1 | 2021 | 35 | 0.190 |
Why?
|
Antibodies, Helminth | 4 | 1989 | 115 | 0.190 |
Why?
|
Ribotyping | 1 | 2021 | 45 | 0.190 |
Why?
|
Esophageal Sphincter, Lower | 1 | 2020 | 11 | 0.180 |
Why?
|
Cell Degranulation | 1 | 2020 | 29 | 0.180 |
Why?
|
Lectins | 1 | 2020 | 49 | 0.180 |
Why?
|
Biomarkers, Tumor | 5 | 2018 | 1430 | 0.180 |
Why?
|
Graves Disease | 1 | 2020 | 16 | 0.180 |
Why?
|
Esophageal Achalasia | 1 | 2020 | 35 | 0.180 |
Why?
|
Esophagoscopy | 4 | 2012 | 157 | 0.180 |
Why?
|
Surgicenters | 1 | 2020 | 4 | 0.180 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 9 | 1996 | 815 | 0.170 |
Why?
|
Lymphoma | 3 | 2012 | 321 | 0.170 |
Why?
|
Lymphocyte Activation | 5 | 1986 | 678 | 0.170 |
Why?
|
Patient Reported Outcome Measures | 1 | 2021 | 164 | 0.170 |
Why?
|
Cryptosporidiosis | 3 | 1995 | 41 | 0.170 |
Why?
|
Time Factors | 16 | 2016 | 6198 | 0.170 |
Why?
|
Strongyloides stercoralis | 3 | 1996 | 21 | 0.170 |
Why?
|
Neoplasms | 1 | 2014 | 2750 | 0.170 |
Why?
|
Brucellosis | 2 | 2014 | 17 | 0.160 |
Why?
|
Epithelium | 8 | 2012 | 366 | 0.160 |
Why?
|
Goblet Cells | 1 | 2020 | 99 | 0.160 |
Why?
|
France | 2 | 2011 | 78 | 0.160 |
Why?
|
Dogs | 7 | 1996 | 763 | 0.160 |
Why?
|
Gerbillinae | 6 | 2007 | 55 | 0.160 |
Why?
|
Neutrophils | 6 | 2016 | 372 | 0.160 |
Why?
|
Clarithromycin | 7 | 1996 | 124 | 0.160 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1998 | 11 | 0.160 |
Why?
|
Opportunistic Infections | 2 | 1989 | 79 | 0.160 |
Why?
|
Lung Diseases, Parasitic | 2 | 1988 | 13 | 0.160 |
Why?
|
Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 1998 | 20 | 0.160 |
Why?
|
Mass Screening | 2 | 2004 | 786 | 0.160 |
Why?
|
In Situ Hybridization | 5 | 1996 | 473 | 0.160 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 1998 | 38 | 0.150 |
Why?
|
Microvilli | 2 | 2017 | 72 | 0.150 |
Why?
|
Microbial Sensitivity Tests | 1 | 2021 | 795 | 0.150 |
Why?
|
Glutarates | 1 | 2018 | 27 | 0.150 |
Why?
|
Intestinal Diseases | 2 | 2015 | 83 | 0.150 |
Why?
|
Reproducibility of Results | 8 | 2014 | 2848 | 0.150 |
Why?
|
Gene Expression | 3 | 2020 | 1569 | 0.150 |
Why?
|
Intestinal Polyps | 3 | 2011 | 29 | 0.150 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 602 | 0.150 |
Why?
|
Diagnostic Errors | 2 | 2012 | 321 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 229 | 0.150 |
Why?
|
Prescriptions | 1 | 2017 | 39 | 0.150 |
Why?
|
Urea | 5 | 2002 | 210 | 0.150 |
Why?
|
Nerve Tissue Proteins | 1 | 2003 | 1115 | 0.140 |
Why?
|
Cytomegalovirus Infections | 3 | 1996 | 217 | 0.140 |
Why?
|
Bile Acids and Salts | 2 | 2010 | 233 | 0.140 |
Why?
|
Tetrazoles | 1 | 2017 | 63 | 0.140 |
Why?
|
Colony Count, Microbial | 3 | 1996 | 89 | 0.140 |
Why?
|
Giardiasis | 1 | 2017 | 10 | 0.140 |
Why?
|
False Negative Reactions | 7 | 2010 | 90 | 0.140 |
Why?
|
Filariasis | 2 | 1988 | 27 | 0.140 |
Why?
|
HIV Seropositivity | 2 | 2014 | 116 | 0.140 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 501 | 0.130 |
Why?
|
Imidazoles | 1 | 2017 | 199 | 0.130 |
Why?
|
Texas | 3 | 2016 | 3542 | 0.130 |
Why?
|
Dog Diseases | 2 | 1988 | 49 | 0.130 |
Why?
|
Consensus | 4 | 2022 | 607 | 0.130 |
Why?
|
Herpesvirus 4, Human | 1 | 1999 | 659 | 0.130 |
Why?
|
Herpes Genitalis | 1 | 1996 | 11 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 864 | 0.130 |
Why?
|
Immunoenzyme Techniques | 5 | 2000 | 262 | 0.130 |
Why?
|
Environment | 1 | 2017 | 143 | 0.130 |
Why?
|
Interleukin-13 | 1 | 2016 | 96 | 0.130 |
Why?
|
Jews | 1 | 2015 | 31 | 0.130 |
Why?
|
Educational Status | 1 | 2017 | 271 | 0.130 |
Why?
|
Indians, North American | 1 | 2015 | 58 | 0.130 |
Why?
|
History, 18th Century | 2 | 2016 | 69 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2006 | 651 | 0.120 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 398 | 0.120 |
Why?
|
Risk | 2 | 2018 | 750 | 0.120 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 1996 | 230 | 0.120 |
Why?
|
Cell Count | 3 | 2023 | 248 | 0.120 |
Why?
|
Coinfection | 1 | 2017 | 171 | 0.120 |
Why?
|
Cell Adhesion Molecules | 1 | 2016 | 225 | 0.120 |
Why?
|
Liver Diseases | 3 | 2014 | 362 | 0.120 |
Why?
|
Antigens, Helminth | 5 | 1994 | 187 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 2 | 2014 | 229 | 0.120 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 392 | 0.120 |
Why?
|
Immune Tolerance | 4 | 1989 | 144 | 0.120 |
Why?
|
Jejunum | 2 | 2013 | 128 | 0.120 |
Why?
|
Phenotype | 8 | 2018 | 4221 | 0.120 |
Why?
|
Population Density | 1 | 2014 | 34 | 0.120 |
Why?
|
Constriction, Pathologic | 1 | 2015 | 238 | 0.120 |
Why?
|
Urethral Neoplasms | 1 | 1994 | 9 | 0.120 |
Why?
|
Rural Health | 1 | 2014 | 47 | 0.110 |
Why?
|
Urban Health | 1 | 2014 | 73 | 0.110 |
Why?
|
Epidemiologic Studies | 1 | 2014 | 42 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2012 | 714 | 0.110 |
Why?
|
Penile Neoplasms | 1 | 1994 | 32 | 0.110 |
Why?
|
DNA, Bacterial | 7 | 2002 | 481 | 0.110 |
Why?
|
Polymerase Chain Reaction | 8 | 2002 | 1586 | 0.110 |
Why?
|
Urinary Bladder Fistula | 1 | 1993 | 4 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 66 | 0.110 |
Why?
|
Algorithms | 2 | 2014 | 1596 | 0.110 |
Why?
|
Pouchitis | 1 | 2013 | 3 | 0.110 |
Why?
|
Proctocolectomy, Restorative | 1 | 2013 | 7 | 0.110 |
Why?
|
Histamine H2 Antagonists | 1 | 2013 | 49 | 0.110 |
Why?
|
Japan | 2 | 2006 | 134 | 0.110 |
Why?
|
Carcinoma, Basal Cell | 1 | 1994 | 70 | 0.110 |
Why?
|
Regression Analysis | 2 | 2012 | 771 | 0.110 |
Why?
|
Intestinal Fistula | 1 | 1993 | 28 | 0.110 |
Why?
|
Statistics, Nonparametric | 3 | 2011 | 426 | 0.100 |
Why?
|
Superinfection | 1 | 1992 | 6 | 0.100 |
Why?
|
Intestinal Perforation | 1 | 1993 | 59 | 0.100 |
Why?
|
Larva | 8 | 1996 | 247 | 0.100 |
Why?
|
Colon, Descending | 1 | 2012 | 3 | 0.100 |
Why?
|
Colon, Ascending | 1 | 2012 | 7 | 0.100 |
Why?
|
Seroepidemiologic Studies | 2 | 2009 | 115 | 0.100 |
Why?
|
Ulcer | 1 | 1992 | 48 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1994 | 191 | 0.100 |
Why?
|
Education, Medical, Continuing | 2 | 2010 | 140 | 0.100 |
Why?
|
Reference Values | 3 | 2007 | 696 | 0.100 |
Why?
|
Climate | 1 | 2012 | 20 | 0.100 |
Why?
|
Poisson Distribution | 1 | 2012 | 48 | 0.100 |
Why?
|
Helminthiasis | 1 | 1993 | 70 | 0.100 |
Why?
|
Inflammation | 5 | 2022 | 1400 | 0.100 |
Why?
|
Penicillins | 3 | 1997 | 154 | 0.100 |
Why?
|
Neoplasm Grading | 1 | 2012 | 267 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2014 | 300 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2012 | 68 | 0.100 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1993 | 162 | 0.100 |
Why?
|
Biomarkers | 4 | 2016 | 2940 | 0.100 |
Why?
|
Cell Division | 3 | 2003 | 779 | 0.100 |
Why?
|
Nuclear Proteins | 1 | 2018 | 1267 | 0.100 |
Why?
|
Mesenteric Veins | 1 | 1991 | 15 | 0.100 |
Why?
|
Receptor, Notch1 | 1 | 2011 | 66 | 0.100 |
Why?
|
Diet | 2 | 2011 | 1125 | 0.090 |
Why?
|
Food Preservation | 1 | 2011 | 4 | 0.090 |
Why?
|
Necatoriasis | 1 | 1991 | 38 | 0.090 |
Why?
|
Chlorogenic Acid | 1 | 2011 | 1 | 0.090 |
Why?
|
Tannins | 1 | 2011 | 2 | 0.090 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 710 | 0.090 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2011 | 27 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 414 | 0.090 |
Why?
|
Pregnancy Complications, Infectious | 1 | 1996 | 443 | 0.090 |
Why?
|
Genes, APC | 1 | 2010 | 13 | 0.090 |
Why?
|
Phenols | 1 | 2011 | 57 | 0.090 |
Why?
|
Gastrointestinal Microbiome | 1 | 2018 | 678 | 0.090 |
Why?
|
Anemia | 1 | 2014 | 339 | 0.090 |
Why?
|
Serologic Tests | 2 | 1988 | 119 | 0.090 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 170 | 0.090 |
Why?
|
Flavonoids | 1 | 2011 | 78 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2013 | 391 | 0.090 |
Why?
|
Homeodomain Proteins | 2 | 2011 | 544 | 0.090 |
Why?
|
Epithelial Cells | 3 | 2010 | 900 | 0.090 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 217 | 0.090 |
Why?
|
Public Health | 1 | 2012 | 261 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 1992 | 317 | 0.090 |
Why?
|
Immunoglobulin A | 2 | 1988 | 197 | 0.090 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2011 | 281 | 0.090 |
Why?
|
Coloring Agents | 4 | 2006 | 77 | 0.090 |
Why?
|
Eicosapentaenoic Acid | 1 | 2010 | 78 | 0.080 |
Why?
|
Oklahoma | 1 | 2009 | 8 | 0.080 |
Why?
|
Esophageal Stenosis | 1 | 2009 | 44 | 0.080 |
Why?
|
District of Columbia | 1 | 2009 | 14 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2012 | 376 | 0.080 |
Why?
|
Cytokines | 3 | 2011 | 1280 | 0.080 |
Why?
|
Hepatitis C | 2 | 2004 | 365 | 0.080 |
Why?
|
International Cooperation | 2 | 2021 | 160 | 0.080 |
Why?
|
Necrosis | 1 | 2009 | 205 | 0.080 |
Why?
|
Cells, Cultured | 5 | 2010 | 3050 | 0.080 |
Why?
|
Nematode Infections | 1 | 1988 | 6 | 0.080 |
Why?
|
Skin | 3 | 1996 | 505 | 0.080 |
Why?
|
Administration, Oral | 2 | 2009 | 671 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 1998 | 1581 | 0.080 |
Why?
|
Consensus Development Conferences as Topic | 2 | 1999 | 39 | 0.080 |
Why?
|
JC Virus | 1 | 2008 | 28 | 0.080 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 2008 | 28 | 0.080 |
Why?
|
Ischemia | 1 | 1991 | 337 | 0.080 |
Why?
|
Feces | 6 | 1996 | 710 | 0.080 |
Why?
|
Lung | 5 | 1989 | 1468 | 0.080 |
Why?
|
DNA Fingerprinting | 3 | 2002 | 108 | 0.070 |
Why?
|
RNA, Messenger | 5 | 2010 | 2820 | 0.070 |
Why?
|
Erythrocebus patas | 2 | 1984 | 4 | 0.070 |
Why?
|
Cercopithecidae | 2 | 1984 | 7 | 0.070 |
Why?
|
Microscopy, Electron | 5 | 2006 | 391 | 0.070 |
Why?
|
Tumor Virus Infections | 1 | 2008 | 134 | 0.070 |
Why?
|
Polyomavirus Infections | 1 | 2008 | 90 | 0.070 |
Why?
|
Repressor Proteins | 1 | 2012 | 811 | 0.070 |
Why?
|
Switzerland | 1 | 2007 | 18 | 0.070 |
Why?
|
Health Services Research | 1 | 2009 | 187 | 0.070 |
Why?
|
Ranitidine | 6 | 1996 | 30 | 0.070 |
Why?
|
Pilot Projects | 1 | 2011 | 1386 | 0.070 |
Why?
|
Cat Diseases | 2 | 1997 | 14 | 0.070 |
Why?
|
Warfare | 1 | 1987 | 35 | 0.070 |
Why?
|
Calcinosis | 1 | 1988 | 167 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2011 | 666 | 0.070 |
Why?
|
Antibody Specificity | 5 | 1988 | 204 | 0.070 |
Why?
|
Immunoglobulins | 2 | 1984 | 168 | 0.070 |
Why?
|
Skin Neoplasms | 1 | 1994 | 804 | 0.070 |
Why?
|
Population Surveillance | 1 | 2009 | 383 | 0.070 |
Why?
|
Cross Reactions | 2 | 2004 | 192 | 0.070 |
Why?
|
Neuroglia | 1 | 2008 | 193 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2003 | 1088 | 0.070 |
Why?
|
Esophagoscopes | 1 | 2006 | 4 | 0.070 |
Why?
|
Vasculitis | 1 | 2006 | 49 | 0.070 |
Why?
|
Myxoma | 1 | 2006 | 28 | 0.070 |
Why?
|
Myenteric Plexus | 2 | 2020 | 12 | 0.070 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2006 | 35 | 0.070 |
Why?
|
Evaluation Studies as Topic | 5 | 1996 | 258 | 0.060 |
Why?
|
Antibodies | 2 | 1989 | 370 | 0.060 |
Why?
|
Smoking | 1 | 2011 | 1032 | 0.060 |
Why?
|
Caco-2 Cells | 2 | 2018 | 96 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2013 | 12087 | 0.060 |
Why?
|
Heart Neoplasms | 1 | 2006 | 101 | 0.060 |
Why?
|
Antibodies, Monoclonal | 4 | 1998 | 1015 | 0.060 |
Why?
|
Europe | 2 | 2000 | 371 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2007 | 279 | 0.060 |
Why?
|
Prostatic Neoplasms | 1 | 1994 | 1515 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2007 | 481 | 0.060 |
Why?
|
Thyroiditis, Autoimmune | 1 | 2004 | 8 | 0.060 |
Why?
|
Microsporidiosis | 2 | 1995 | 6 | 0.060 |
Why?
|
Monocytes | 2 | 1999 | 347 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 1684 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 687 | 0.060 |
Why?
|
Mice, Inbred C57BL | 5 | 2013 | 4342 | 0.060 |
Why?
|
Carcinoma | 3 | 2010 | 278 | 0.060 |
Why?
|
Lithostathine | 1 | 2003 | 2 | 0.060 |
Why?
|
Gastric Acidity Determination | 1 | 2003 | 19 | 0.060 |
Why?
|
Genetic Testing | 1 | 2010 | 995 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2006 | 293 | 0.060 |
Why?
|
Hepatitis B virus | 2 | 1996 | 137 | 0.060 |
Why?
|
Tumor Burden | 2 | 2017 | 230 | 0.060 |
Why?
|
Models, Biological | 2 | 2003 | 1441 | 0.060 |
Why?
|
Cytomegalovirus | 3 | 1996 | 268 | 0.060 |
Why?
|
Mice | 8 | 2018 | 17469 | 0.050 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 88 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2004 | 180 | 0.050 |
Why?
|
Brazil | 2 | 2018 | 121 | 0.050 |
Why?
|
Fundoplication | 2 | 2019 | 66 | 0.050 |
Why?
|
Comprehension | 1 | 2023 | 74 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2006 | 261 | 0.050 |
Why?
|
Immunity, Cellular | 3 | 1992 | 203 | 0.050 |
Why?
|
Isoenzymes | 1 | 2003 | 223 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 2000 | 1063 | 0.050 |
Why?
|
Thymidine Phosphorylase | 1 | 2002 | 12 | 0.050 |
Why?
|
Base Sequence | 3 | 2003 | 3093 | 0.050 |
Why?
|
alpha 1-Antichymotrypsin | 1 | 2002 | 4 | 0.050 |
Why?
|
Chest Pain | 1 | 2023 | 125 | 0.050 |
Why?
|
Prednisolone | 3 | 1989 | 73 | 0.050 |
Why?
|
Sequence Alignment | 1 | 2003 | 623 | 0.050 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2002 | 37 | 0.050 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2022 | 70 | 0.050 |
Why?
|
Survival Analysis | 2 | 2018 | 1470 | 0.050 |
Why?
|
DNA, Viral | 3 | 2008 | 477 | 0.050 |
Why?
|
Rats | 5 | 2009 | 3629 | 0.050 |
Why?
|
Antigens, Surface | 1 | 1982 | 122 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2002 | 138 | 0.050 |
Why?
|
Carcinogenesis | 1 | 2024 | 328 | 0.050 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2002 | 57 | 0.050 |
Why?
|
Neutrophil Infiltration | 1 | 2002 | 65 | 0.050 |
Why?
|
Fixatives | 1 | 2021 | 14 | 0.050 |
Why?
|
Forecasting | 3 | 1997 | 355 | 0.050 |
Why?
|
Formaldehyde | 1 | 2021 | 31 | 0.050 |
Why?
|
Methylnitrosourea | 1 | 2001 | 19 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2020 | 1585 | 0.050 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 149 | 0.050 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2020 | 16 | 0.050 |
Why?
|
Purpura, Thrombocytopenic | 1 | 2000 | 7 | 0.050 |
Why?
|
Trefoil Factor-2 | 1 | 2020 | 9 | 0.050 |
Why?
|
Up-Regulation | 1 | 2003 | 867 | 0.050 |
Why?
|
Host-Parasite Interactions | 2 | 1992 | 68 | 0.050 |
Why?
|
Lipid Peroxidation | 2 | 2011 | 82 | 0.050 |
Why?
|
Quality of Life | 2 | 2021 | 1926 | 0.050 |
Why?
|
Receptors, Thyrotropin | 1 | 2020 | 11 | 0.040 |
Why?
|
Agar | 2 | 1997 | 16 | 0.040 |
Why?
|
Hot Temperature | 2 | 1996 | 135 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2003 | 3871 | 0.040 |
Why?
|
Liver Transplantation | 2 | 2006 | 1008 | 0.040 |
Why?
|
Desipramine | 1 | 2019 | 27 | 0.040 |
Why?
|
Antitrichomonal Agents | 2 | 1997 | 10 | 0.040 |
Why?
|
2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2016 | 27 | 0.040 |
Why?
|
Molecular Biology | 1 | 2000 | 77 | 0.040 |
Why?
|
Muscle Relaxants, Central | 1 | 2019 | 33 | 0.040 |
Why?
|
Histocytological Preparation Techniques | 1 | 1999 | 5 | 0.040 |
Why?
|
Baclofen | 1 | 2019 | 39 | 0.040 |
Why?
|
Environmental Exposure | 1 | 2021 | 218 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2020 | 399 | 0.040 |
Why?
|
Liver Function Tests | 2 | 2014 | 101 | 0.040 |
Why?
|
Neutrophil Activation | 1 | 1999 | 16 | 0.040 |
Why?
|
Family | 1 | 2002 | 576 | 0.040 |
Why?
|
Autopsy | 2 | 2016 | 110 | 0.040 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 1999 | 8 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 533 | 0.040 |
Why?
|
Fatal Outcome | 2 | 2000 | 357 | 0.040 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 12 | 0.040 |
Why?
|
CA-19-9 Antigen | 1 | 1998 | 10 | 0.040 |
Why?
|
Surgical Instruments | 1 | 1999 | 57 | 0.040 |
Why?
|
Drug Resistance | 1 | 2019 | 256 | 0.040 |
Why?
|
Fiber Optic Technology | 1 | 1999 | 46 | 0.040 |
Why?
|
Genes, Immunoglobulin | 1 | 1998 | 33 | 0.040 |
Why?
|
Immunoblotting | 2 | 1989 | 312 | 0.040 |
Why?
|
Glycosylation | 1 | 1998 | 113 | 0.040 |
Why?
|
Cell Proliferation | 2 | 2018 | 2306 | 0.040 |
Why?
|
Antigens, CD | 1 | 2020 | 420 | 0.040 |
Why?
|
Drug Resistance, Bacterial | 1 | 2021 | 360 | 0.040 |
Why?
|
Korea | 1 | 1998 | 35 | 0.040 |
Why?
|
Cell Line | 3 | 2013 | 2779 | 0.040 |
Why?
|
Bacteriological Techniques | 2 | 1995 | 91 | 0.040 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1989 | 313 | 0.040 |
Why?
|
Airway Remodeling | 1 | 2018 | 20 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 1998 | 65 | 0.040 |
Why?
|
Azoxymethane | 1 | 2018 | 10 | 0.040 |
Why?
|
Adenoma, Villous | 1 | 2017 | 2 | 0.040 |
Why?
|
Bronchi | 1 | 1998 | 99 | 0.040 |
Why?
|
Dextran Sulfate | 1 | 2018 | 46 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 99 | 0.040 |
Why?
|
Furazolidone | 1 | 1997 | 8 | 0.040 |
Why?
|
Remission Induction | 2 | 2013 | 300 | 0.040 |
Why?
|
Acute Disease | 3 | 2014 | 1089 | 0.040 |
Why?
|
Promoter Regions, Genetic | 2 | 2011 | 1335 | 0.040 |
Why?
|
Southeastern United States | 1 | 2017 | 38 | 0.040 |
Why?
|
Vietnam | 2 | 1987 | 44 | 0.030 |
Why?
|
Clinical Enzyme Tests | 1 | 1996 | 14 | 0.030 |
Why?
|
Drug Administration Schedule | 5 | 1996 | 730 | 0.030 |
Why?
|
HIV Enteropathy | 1 | 1996 | 2 | 0.030 |
Why?
|
Transcription Factors | 1 | 2007 | 2577 | 0.030 |
Why?
|
Phosphorylation | 2 | 2013 | 1610 | 0.030 |
Why?
|
False Positive Reactions | 4 | 1997 | 145 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 1998 | 325 | 0.030 |
Why?
|
Pain Measurement | 1 | 1998 | 349 | 0.030 |
Why?
|
NF-kappa B | 2 | 2010 | 459 | 0.030 |
Why?
|
Herpesvirus 2, Human | 1 | 1996 | 13 | 0.030 |
Why?
|
Fibrosis | 1 | 2018 | 429 | 0.030 |
Why?
|
Epidemiologic Factors | 1 | 1995 | 8 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2016 | 67 | 0.030 |
Why?
|
Ampulla of Vater | 1 | 1995 | 16 | 0.030 |
Why?
|
Common Bile Duct Neoplasms | 1 | 1995 | 9 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2012 | 2391 | 0.030 |
Why?
|
Audiovisual Aids | 1 | 1996 | 25 | 0.030 |
Why?
|
Urban Population | 1 | 2017 | 219 | 0.030 |
Why?
|
Virus Replication | 2 | 1996 | 600 | 0.030 |
Why?
|
Cell Survival | 1 | 2018 | 803 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 1998 | 518 | 0.030 |
Why?
|
Fetal Death | 1 | 1996 | 113 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2002 | 819 | 0.030 |
Why?
|
Surveys and Questionnaires | 3 | 2019 | 3657 | 0.030 |
Why?
|
Cell Lineage | 1 | 2017 | 341 | 0.030 |
Why?
|
Sodium Bicarbonate | 1 | 1995 | 52 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2010 | 3090 | 0.030 |
Why?
|
Fasting | 1 | 1996 | 296 | 0.030 |
Why?
|
Azithromycin | 1 | 1995 | 45 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2007 | 1695 | 0.030 |
Why?
|
DNA Methylation | 2 | 2011 | 991 | 0.030 |
Why?
|
Antigens, Viral | 2 | 1994 | 436 | 0.030 |
Why?
|
Brucella melitensis | 1 | 2014 | 8 | 0.030 |
Why?
|
Rural Population | 1 | 2017 | 249 | 0.030 |
Why?
|
Autoimmunity | 1 | 2015 | 172 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1999 | 1067 | 0.030 |
Why?
|
Fetal Diseases | 1 | 1998 | 440 | 0.030 |
Why?
|
Pregnancy | 2 | 1998 | 7115 | 0.030 |
Why?
|
Hepatovirus | 1 | 1994 | 17 | 0.030 |
Why?
|
Cell Movement | 1 | 2018 | 831 | 0.030 |
Why?
|
Gallbladder | 1 | 1994 | 19 | 0.030 |
Why?
|
Parasite Egg Count | 2 | 1995 | 28 | 0.030 |
Why?
|
Geographic Information Systems | 1 | 2014 | 40 | 0.030 |
Why?
|
Cholecystitis | 1 | 1994 | 20 | 0.030 |
Why?
|
Complement System Proteins | 1 | 1994 | 58 | 0.030 |
Why?
|
Microsporida | 1 | 1993 | 2 | 0.030 |
Why?
|
Complement Activation | 1 | 1994 | 52 | 0.030 |
Why?
|
Keratin-18 | 1 | 2013 | 6 | 0.030 |
Why?
|
Keratin-14 | 1 | 2013 | 8 | 0.030 |
Why?
|
Hepatitis B Antigens | 1 | 1993 | 10 | 0.030 |
Why?
|
Keratin-8 | 1 | 2013 | 11 | 0.030 |
Why?
|
Achlorhydria | 1 | 1993 | 6 | 0.030 |
Why?
|
Carbon Isotopes | 3 | 2002 | 271 | 0.030 |
Why?
|
Phospholipase C gamma | 1 | 2013 | 17 | 0.030 |
Why?
|
Bile Ducts | 1 | 1994 | 54 | 0.030 |
Why?
|
Autocrine Communication | 1 | 2013 | 27 | 0.030 |
Why?
|
Urethra | 1 | 1994 | 82 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 1996 | 571 | 0.030 |
Why?
|
New York | 1 | 2013 | 68 | 0.030 |
Why?
|
Homosexuality | 1 | 1993 | 18 | 0.030 |
Why?
|
Dental Plaque | 1 | 1993 | 5 | 0.030 |
Why?
|
Body Weight | 2 | 1988 | 999 | 0.030 |
Why?
|
Penis | 1 | 1994 | 97 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 1 | 1993 | 39 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 678 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2013 | 169 | 0.030 |
Why?
|
SOX9 Transcription Factor | 1 | 2013 | 79 | 0.030 |
Why?
|
Cryptosporidium | 1 | 1993 | 32 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 150 | 0.030 |
Why?
|
Liver | 3 | 1996 | 1727 | 0.030 |
Why?
|
Intestinal Absorption | 2 | 1995 | 190 | 0.030 |
Why?
|
Patient Compliance | 2 | 1995 | 468 | 0.030 |
Why?
|
Helminths | 1 | 1993 | 44 | 0.030 |
Why?
|
Workload | 1 | 2013 | 147 | 0.030 |
Why?
|
Indoles | 1 | 2013 | 181 | 0.030 |
Why?
|
Hepatitis B | 1 | 1993 | 160 | 0.020 |
Why?
|
Hoarseness | 1 | 2012 | 11 | 0.020 |
Why?
|
Transcription Factor HES-1 | 1 | 2011 | 16 | 0.020 |
Why?
|
Pyrroles | 1 | 2013 | 177 | 0.020 |
Why?
|
Probability | 2 | 2004 | 322 | 0.020 |
Why?
|
Serrate-Jagged Proteins | 1 | 2011 | 38 | 0.020 |
Why?
|
Azacitidine | 1 | 2011 | 54 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 1993 | 327 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 319 | 0.020 |
Why?
|
Jagged-1 Protein | 1 | 2011 | 51 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 1991 | 20 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 2012 | 69 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 515 | 0.020 |
Why?
|
Polyphenols | 1 | 2011 | 19 | 0.020 |
Why?
|
Prostate | 1 | 1994 | 421 | 0.020 |
Why?
|
Cough | 1 | 2012 | 86 | 0.020 |
Why?
|
Drinking | 1 | 2011 | 34 | 0.020 |
Why?
|
Genotype | 2 | 2010 | 2546 | 0.020 |
Why?
|
Macaca | 1 | 2011 | 62 | 0.020 |
Why?
|
Pneumonia, Viral | 1 | 1996 | 376 | 0.020 |
Why?
|
DNA | 1 | 1996 | 1592 | 0.020 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2010 | 136 | 0.020 |
Why?
|
CDX2 Transcription Factor | 1 | 2010 | 9 | 0.020 |
Why?
|
Genetic Techniques | 1 | 2010 | 107 | 0.020 |
Why?
|
Refugees | 1 | 1990 | 32 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2010 | 112 | 0.020 |
Why?
|
Duodenostomy | 1 | 2009 | 1 | 0.020 |
Why?
|
Esophagostomy | 1 | 2009 | 2 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 156 | 0.020 |
Why?
|
Escherichia coli | 1 | 1995 | 980 | 0.020 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2009 | 61 | 0.020 |
Why?
|
Latin America | 1 | 1989 | 89 | 0.020 |
Why?
|
Asia | 1 | 1989 | 107 | 0.020 |
Why?
|
Africa | 1 | 1989 | 129 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 377 | 0.020 |
Why?
|
Gastrointestinal Agents | 1 | 2009 | 60 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 347 | 0.020 |
Why?
|
Strongyloidea | 1 | 1988 | 1 | 0.020 |
Why?
|
Sucrase | 1 | 1988 | 22 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 224 | 0.020 |
Why?
|
RNA Interference | 1 | 2010 | 496 | 0.020 |
Why?
|
Microdissection | 1 | 2008 | 12 | 0.020 |
Why?
|
beta-Galactosidase | 1 | 1988 | 143 | 0.020 |
Why?
|
Alkaline Phosphatase | 1 | 1988 | 96 | 0.020 |
Why?
|
Methylprednisolone | 1 | 1988 | 90 | 0.020 |
Why?
|
Manometry | 1 | 2008 | 48 | 0.020 |
Why?
|
Carbon Dioxide | 2 | 2002 | 273 | 0.020 |
Why?
|
Emigration and Immigration | 1 | 1968 | 81 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2009 | 287 | 0.020 |
Why?
|
Thailand | 1 | 1987 | 34 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 2 | 1993 | 462 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 1987 | 111 | 0.020 |
Why?
|
Upstream Stimulatory Factors | 1 | 2007 | 8 | 0.020 |
Why?
|
E2F Transcription Factors | 1 | 2007 | 24 | 0.020 |
Why?
|
Cats | 2 | 1997 | 117 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2007 | 41 | 0.020 |
Why?
|
Immunoassay | 1 | 1987 | 127 | 0.020 |
Why?
|
Radioallergosorbent Test | 1 | 1986 | 7 | 0.020 |
Why?
|
Basophils | 2 | 1984 | 12 | 0.020 |
Why?
|
Interferon Regulatory Factors | 1 | 2007 | 40 | 0.020 |
Why?
|
Prednisone | 2 | 1984 | 273 | 0.020 |
Why?
|
Transcription Factor AP-1 | 1 | 2007 | 106 | 0.020 |
Why?
|
Morbidity | 1 | 2007 | 240 | 0.020 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 110 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2007 | 101 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 1986 | 109 | 0.020 |
Why?
|
Digestive System | 1 | 1986 | 59 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 2 | 1996 | 53 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2009 | 1211 | 0.020 |
Why?
|
Methylene Blue | 1 | 2006 | 13 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2006 | 106 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 207 | 0.020 |
Why?
|
Blotting, Southern | 2 | 1997 | 214 | 0.020 |
Why?
|
Long-Term Care | 1 | 2005 | 71 | 0.020 |
Why?
|
Spleen | 2 | 1984 | 272 | 0.020 |
Why?
|
Esophageal and Gastric Varices | 1 | 2006 | 64 | 0.020 |
Why?
|
Microscopy | 1 | 2006 | 118 | 0.020 |
Why?
|
Intracranial Aneurysm | 1 | 1986 | 93 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 1986 | 210 | 0.020 |
Why?
|
Immunologic Techniques | 1 | 1984 | 10 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2006 | 348 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2006 | 239 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2005 | 202 | 0.010 |
Why?
|
Iodide Peroxidase | 1 | 2004 | 8 | 0.010 |
Why?
|
Haplorhini | 1 | 1984 | 123 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 3283 | 0.010 |
Why?
|
Molecular Mimicry | 1 | 2004 | 24 | 0.010 |
Why?
|
Iron-Binding Proteins | 1 | 2004 | 32 | 0.010 |
Why?
|
Treatment Failure | 2 | 1995 | 338 | 0.010 |
Why?
|
Lymph Nodes | 2 | 1984 | 374 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 1675 | 0.010 |
Why?
|
Skin Tests | 1 | 1984 | 75 | 0.010 |
Why?
|
Asthma | 1 | 2012 | 746 | 0.010 |
Why?
|
Genomic Instability | 1 | 2005 | 229 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1874 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2011 | 1915 | 0.010 |
Why?
|
Actins | 1 | 2006 | 341 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2011 | 1524 | 0.010 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 23 | 0.010 |
Why?
|
Phytohemagglutinins | 1 | 1983 | 12 | 0.010 |
Why?
|
Antibody Formation | 1 | 1984 | 256 | 0.010 |
Why?
|
Tuberculin | 1 | 1983 | 12 | 0.010 |
Why?
|
Cyclooxygenase 1 | 1 | 2003 | 40 | 0.010 |
Why?
|
Tetanus Toxoid | 1 | 1983 | 45 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 1013 | 0.010 |
Why?
|
Histamine Release | 1 | 1983 | 10 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2004 | 424 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1294 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2006 | 515 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 1983 | 68 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2003 | 158 | 0.010 |
Why?
|
Antigens | 1 | 1983 | 156 | 0.010 |
Why?
|
Thiabendazole | 1 | 1982 | 2 | 0.010 |
Why?
|
Global Health | 1 | 2007 | 557 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2002 | 152 | 0.010 |
Why?
|
Proton Pumps | 1 | 2002 | 11 | 0.010 |
Why?
|
Age of Onset | 1 | 2004 | 581 | 0.010 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2002 | 107 | 0.010 |
Why?
|
Virulence | 1 | 2002 | 259 | 0.010 |
Why?
|
Physicians | 1 | 1968 | 583 | 0.010 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2002 | 95 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2006 | 670 | 0.010 |
Why?
|
Demography | 1 | 2002 | 239 | 0.010 |
Why?
|
Microscopy, Fluorescence | 2 | 1993 | 330 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2002 | 367 | 0.010 |
Why?
|
Respiration | 1 | 2002 | 123 | 0.010 |
Why?
|
Arteries | 1 | 2002 | 222 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 2533 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2003 | 266 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 2000 | 113 | 0.010 |
Why?
|
Mice, Inbred CBA | 1 | 1999 | 30 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1999 | 118 | 0.010 |
Why?
|
Macrophage-1 Antigen | 1 | 1999 | 26 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2000 | 219 | 0.010 |
Why?
|
Cerebral Hemorrhage | 1 | 2000 | 142 | 0.010 |
Why?
|
CD18 Antigens | 1 | 1999 | 49 | 0.010 |
Why?
|
Signal Transduction | 1 | 2011 | 4507 | 0.010 |
Why?
|
Colonoscopes | 1 | 1999 | 9 | 0.010 |
Why?
|
Equipment Safety | 1 | 1999 | 37 | 0.010 |
Why?
|
Culture Techniques | 1 | 1999 | 90 | 0.010 |
Why?
|
Species Specificity | 1 | 1999 | 549 | 0.010 |
Why?
|
Azure Stains | 1 | 1998 | 4 | 0.010 |
Why?
|
Medical Laboratory Personnel | 1 | 1998 | 10 | 0.010 |
Why?
|
Histological Techniques | 1 | 1998 | 20 | 0.010 |
Why?
|
Medical Laboratory Science | 1 | 1998 | 13 | 0.010 |
Why?
|
Chaperonin 60 | 1 | 1997 | 32 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 1997 | 76 | 0.010 |
Why?
|
Pentagastrin | 1 | 1997 | 6 | 0.010 |
Why?
|
Antacids | 1 | 1997 | 26 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2000 | 435 | 0.010 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 1997 | 50 | 0.010 |
Why?
|
Zoonoses | 1 | 1997 | 43 | 0.010 |
Why?
|
Oviposition | 1 | 1996 | 6 | 0.010 |
Why?
|
Lansoprazole | 1 | 1996 | 22 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1997 | 193 | 0.010 |
Why?
|
Clinical Laboratory Techniques | 1 | 1998 | 143 | 0.010 |
Why?
|
Adhesins, Bacterial | 1 | 1997 | 75 | 0.010 |
Why?
|
Equipment Design | 1 | 1999 | 599 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1997 | 280 | 0.010 |
Why?
|
Gels | 1 | 1996 | 60 | 0.010 |
Why?
|
DNA Probes | 1 | 1996 | 124 | 0.010 |
Why?
|
Parasites | 1 | 1996 | 29 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1996 | 37 | 0.010 |
Why?
|
Arthritis | 1 | 1996 | 80 | 0.010 |
Why?
|
Enterovirus | 1 | 1996 | 48 | 0.010 |
Why?
|
Fungi | 1 | 1996 | 69 | 0.010 |
Why?
|
Single-Blind Method | 1 | 1996 | 234 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1996 | 159 | 0.010 |
Why?
|
India | 1 | 1996 | 217 | 0.010 |
Why?
|
Organ Specificity | 1 | 1996 | 423 | 0.010 |
Why?
|
Adhesins, Escherichia coli | 1 | 1995 | 19 | 0.010 |
Why?
|
RNA, Ribosomal, 16S | 1 | 1997 | 372 | 0.010 |
Why?
|
Bronchoscopy | 1 | 1996 | 156 | 0.010 |
Why?
|
Research | 1 | 1997 | 263 | 0.010 |
Why?
|
Xylose | 1 | 1995 | 9 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1996 | 300 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 1996 | 133 | 0.010 |
Why?
|
Mannitol | 1 | 1995 | 48 | 0.010 |
Why?
|
Lactulose | 1 | 1995 | 39 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1995 | 55 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 1995 | 83 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1997 | 1002 | 0.010 |
Why?
|
Random Allocation | 1 | 1995 | 423 | 0.010 |
Why?
|
Immunoelectrophoresis | 1 | 1994 | 12 | 0.010 |
Why?
|
Edetic Acid | 1 | 1994 | 23 | 0.010 |
Why?
|
Egtazic Acid | 1 | 1994 | 25 | 0.010 |
Why?
|
ROC Curve | 1 | 1996 | 556 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1995 | 396 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1994 | 105 | 0.010 |
Why?
|
Gastric Juice | 1 | 1993 | 13 | 0.010 |
Why?
|
CD4 Antigens | 1 | 1993 | 55 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1996 | 223 | 0.010 |
Why?
|
RNA, Viral | 1 | 1996 | 540 | 0.010 |
Why?
|
Body Water | 1 | 1993 | 88 | 0.010 |
Why?
|
Hepatoblastoma | 1 | 1996 | 178 | 0.010 |
Why?
|
Cell Cycle | 1 | 1996 | 611 | 0.010 |
Why?
|
Paromomycin | 1 | 1993 | 3 | 0.010 |
Why?
|
Ammonia | 1 | 1993 | 68 | 0.010 |
Why?
|
Cell Adhesion | 1 | 1994 | 321 | 0.010 |
Why?
|
Protein Precursors | 1 | 1993 | 149 | 0.010 |
Why?
|
Food | 1 | 1993 | 125 | 0.010 |
Why?
|
Immunochemistry | 1 | 1991 | 30 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 1993 | 354 | 0.010 |
Why?
|
Antiviral Agents | 1 | 1996 | 736 | 0.010 |
Why?
|
Asia, Southeastern | 1 | 1990 | 20 | 0.010 |
Why?
|
Canada | 1 | 1990 | 294 | 0.010 |
Why?
|
Sweden | 1 | 1968 | 33 | 0.000 |
Why?
|
Foreign Medical Graduates | 1 | 1968 | 11 | 0.000 |
Why?
|
Medullary Sponge Kidney | 1 | 1986 | 2 | 0.000 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1995 | 927 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 1996 | 1300 | 0.000 |
Why?
|